Listen Listen
Add to my selection
  • History
  • Technical informations
Share Print

TAGRISSO

Medicine - Posted on May 30 2022
Active substance (DCI)
  • osimertinib
history (4)
  • Economic analysis
    1/19/22

    TAGRISSO (osimertinib) - Cancer bronchique non à petites cellules (CBNPC)
    Key points Favourable opinion for reimbursement only in the adjuvant treatment after complete tumour resection and after adj...
    CAV :
    54321
    icône flèche
  • 3/20/20

    TAGRISSO (osimertinib)
    Key points Favourable opinion for reimbursement as monotherapy in the first-line treatment of adult patients with locally ad...
    CAV :
    54321
    icône flèche
  • Economic analysis
    9/13/17

    TAGRISSO (osimertinib), tyrosine kinase inhibitor
    Substantial actual benefit and minor improvement compared with chemotherapy combining a platinum salt with pemetrexed in pat...
    CAV :
    54321
    icône flèche
  • Economic analysis
    9/21/16

    TAGRISSO (osimertinib), tyrosine kinase inhibitor
    No clinical benefit demonstrated in the treatment of locally-advanced or metastatic non-small cell lung cancer with EGFR T79...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L01EB04
Manufacturer
ASTRAZENECA
Presentation

TAGRISSO 40 mg, comprimés pelliculés
30 plaquettes aluminium de 1 comprimé - (Code CIP : 34009 300 476 4 4)

TAGRISSO 80 mg, comprimés pelliculés
30 plaquettes aluminium de 1 comprimé - (Code CIP : 34009 300 476 5 1)

All our publications
    Drug therapy Health economics Respiratory tract cancers
  • fr Français
  • en English
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
H1VPAm74T30pFD9m